Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
Syndax Pharmaceuticals (NASDAQ:SNDX) was downgraded by analysts at
Wall
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference